ATTAIN-MAINTAIN Trial
Cross-source consensus on ATTAIN-MAINTAIN Trial from 1 sources and 5 claims.
1 sources · 5 claims
Evidence quality
Where it comes from
Highlighted claims
- ATTAIN-MAINTAIN was a phase 3b randomized, double-blind, placebo-controlled trial at 29 sites in the United States. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- The study screened 400 participants and enrolled 376 between September 13, 2024, and November 21, 2025. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- The trial enrolled participants who had completed SURMOUNT-5 after 72 weeks of tirzepatide or semaglutide injectable therapy. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- The two prior-therapy cohorts were treated and analyzed independently. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Eligible adults had completed SURMOUNT-5 on study treatment and had lost at least 5% of body weight by week 72. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial